Fertility sparing management of high grade serous carcinoma of ovary
Reading File
Finding Sources
Finding Sources
Searching PubMed
"fertility sparing" AND "high grade serous" AND "ovarian cancer"
Reading File
Reading File
Searching PubMed
"fertility preservation" AND "ovarian cancer" AND "serous"
Reading File
Finding Sources
Reading Article
Reading Article
Reading File
Finding Sources
Searching PubMed
"fertility sparing" AND "high grade serous ovarian" AND surgery
Reading File
Finding Sources
Searching the Web
fertility sparing surgery high grade serous ovarian carcinoma stage I guidelines 2024 2025
Reading Web Page
high grade serous ovarian carcinoma fertility sparing surgery criteria recommendations
Searching PubMed
"BRCA" AND "fertility sparing" AND "ovarian" AND "serous"
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive data. Let me compile the full answer.
Fertility-Sparing Management of High-Grade Serous Carcinoma (HGSC) of the Ovary
Overview and the Central Paradox
High-grade serous carcinoma (HGSC) is the most aggressive and most common subtype of epithelial ovarian cancer, accounting for >70% of advanced-stage disease. It poses the greatest tension in fertility-sparing (FS) decisions: the histology carries the worst prognosis, yet the growing trend of delayed childbearing means more young women are being diagnosed at early stages and asking about preserving their uterus and contralateral ovary.
The standard oncologic surgery — total abdominal hysterectomy + bilateral salpingo-oophorectomy (TAH + BSO) + comprehensive staging — remains the default. FS surgery is an individualized, carefully selected deviation from this standard.
1. Pathological Context: Why HGSC Is High Risk
- HGSC arises predominantly from the fimbriated end of the fallopian tube via serous tubal intraepithelial carcinoma (STIC) — a pre-invasive lesion. This origin (not the ovary surface) has major implications: the fallopian tube itself is the primary site, and both tubes should be removed even in FS surgery.
- TP53 mutations are virtually ubiquitous (>95%) in HGSC.
- BRCA1/2 germline mutations are found in ~15–20% of HGSC patients; BRCA1-associated HGSC shows brisk lymphocytic infiltration and marked nuclear pleomorphism (Berek & Novak's Gynecology).
- Unlike low-grade serous carcinoma, HGSC is a type II tumor with rapid progression, high metastatic potential, and frequent upstaging: 16% of grade 1 tumors are upstaged at formal restaging surgery vs. 46% of grade 3 tumors (Berek & Novak's Gynecology).
2. When Is Fertility-Sparing Surgery Permissible in HGSC?
Current Framework — ESGO/ESHRE/ESGE 2024 Guidelines
The most up-to-date international guidance (Lancet Oncology, 2024) classifies HGSC into three tiers:
| FIGO Stage | Recommendation | Evidence Level |
|---|---|---|
| Stage IA | Favourable — FS surgery acceptable | IV, B |
| Stage IC2 (intraoperative rupture) | Acceptable in selected cases | IV, C |
| Stage IC3 (pre-operative rupture / positive cytology) | Unfavourable — FS contraindicated | IV, B |
| Stage IB, II–IV | Unfavourable — FS contraindicated | IV, B |
Key point: HGSC stage IA is the only stage where FS surgery is considered a standard option; IC2 requires careful case selection and shared decision-making; IC3 and higher stages are explicitly contraindicated for FS (ESGO/ESHRE/ESGE Pocket Guidelines, 2025).
NCCN 2025 Position
The NCCN 2025 patient guidelines state: "Fertility-sparing surgery may be an option if the cancer hasn't spread beyond the ovary." Standard histology high-grade serous/high-grade endometrioid are primarily treated with surgery + chemotherapy; FS is acknowledged as an option for early-stage disease.
3. Surgical Technique of FS Surgery in HGSC
What is Preserved
- Uterus (intact, with normal endometrial evaluation recommended — ideally hysteroscopy pre-operatively)
- Contralateral (uninvolved) ovary — only if it appears normal
- If uterine preservation is desired but bilateral oophorectomy is oncologically necessary (e.g., bilateral STIC or bilateral disease), BSO + uterine preservation is acceptable if endometrium and uterine serosa are normal (ESGO/ESHRE/ESGE, [IV, B])
What Must Be Removed
- Ipsilateral salpingo-oophorectomy (USO) — the affected adnexa completely
- Complete surgical staging is mandatory — this is non-negotiable:
- Peritoneal washings / ascites cytology
- Multiple peritoneal biopsies (cul-de-sac, paracolic gutters, bladder peritoneum, mesenteric surfaces)
- Diaphragm sampling (biopsy or scraping)
- Infracolic omentectomy (supracolic omentectomy preferred)
- Pelvic and para-aortic lymph node dissection — enlarged nodes require sampling; formal lymphadenectomy if no macroscopic metastases (Berek & Novak's Gynecology, p. 2335)
- Inspection and biopsy of any adhesions or suspicious areas
Importance of Thorough Staging
Up to 30% of apparent stage I disease is upstaged on comprehensive surgical staging. Among grade 3 tumors (which includes HGSC), the upstaging rate reaches 46%. Incomplete staging is the most common error and the most important contraindication to FS surgery.
4. Oncologic Outcomes of FS Surgery in HGSC
The largest population-level evidence comes from the SEER database (Song et al., Obstetrics and Gynecology, 2024 [PMID: 38781594]):
- Among 3,027 reproductive-age patients with stage I epithelial ovarian cancer (2007–2020), 17.6% underwent FS surgery
- FS surgery utilization in high-grade serous histology increased 2.2-fold over the study period (P for trend <0.05)
- 5-year overall survival for HGSC: FS surgery group 92.9% vs. non-sparing surgery 92.4% — no significant difference (P >0.05)
- Important contrast: high-grade endometrioid tumors had decreased survival with FS surgery (adjusted HR 2.90), highlighting histology-specific considerations
These data provide population-level reassurance that HGSC stage IA treated with FS surgery does not compromise survival compared to radical surgery when staging is complete.
5. Adjuvant Chemotherapy
After FS surgery, the chemotherapy decision follows standard HGSC protocols:
| Risk Group | Recommendation |
|---|---|
| Stage IA, grade 1–2 (low-risk) | Observation may be acceptable |
| Stage IA HGSC (grade 3) | Adjuvant chemotherapy recommended |
| Stage IC (any high-grade) | Adjuvant chemotherapy mandatory |
| Stage II–IV | Full platinum-based chemotherapy (paclitaxel + carboplatin ×6 cycles) |
HGSC at stage IA is classified as high-risk disease due to grade 3 histology; adjuvant paclitaxel + carboplatin (typically 3–6 cycles) is the standard of care even after FS surgery (Berek & Novak's Gynecology; NCCN 2025).
6. Special Consideration: BRCA Mutation Carriers
This is one of the most important nuances in HGSC FS management:
- ~15–20% of HGSC patients carry BRCA1/2 germline mutations
- All women with HGSC (excluding mucinous type) should be offered germline genetic testing regardless of family history (Berek & Novak's Gynecology, p. 2329)
- BRCA1 carriers have the highest lifetime ovarian cancer risk and develop it earlier (peak ~40–50s); BRCA2 carriers trend later
- ESGO/ESHRE/ESGE 2024 guidelines make a notable exception: unilateral tubo-ovarian carcinoma or STIC in patients <40 years with high-risk germline mutation may be acceptable for FS surgery in selected cases (IC, [IV, C])
- After FS surgery and completion of childbearing, risk-reducing BSO (at age 35–40 for BRCA1; 40–45 for BRCA2) is strongly recommended
- Patients should be counseled that even after risk-reducing surgery, peritoneal carcinoma can still occur
PARP inhibitors (olaparib, niraparib, rucaparib) as maintenance therapy after platinum-based chemotherapy are indicated in BRCA-mutated HGSC and should be offered regardless of FS surgery status.
7. Fertility Preservation Techniques (Adjunct to FS Surgery)
Where chemotherapy is planned, fertility preservation prior to starting treatment should be discussed:
- Embryo cryopreservation — preferred; requires partner/donor sperm
- Oocyte cryopreservation — standard option for single women
- Ovarian tissue cryopreservation — emerging; not preferred in HGSC due to theoretical risk of reimplanting malignant cells from STIC or occult cortical disease
- Referral to a reproductive medicine specialist should occur urgently before chemotherapy begins (ESGO/ESHRE/ESGE recommendation)
8. Follow-Up After FS Surgery
- Transvaginal ultrasonography every 3–6 months for the first 2 years, then every 6 months
- Serum CA-125 at each follow-up visit
- Contralateral ovary inspection annually
- Completion surgery (hysterectomy + BSO) after childbearing is complete — this is standard recommendation
- Patients with BRCA mutations require additional breast surveillance (annual mammography + MRI from age 30)
9. Patient Selection Summary
| Criterion | Requirement |
|---|---|
| FIGO stage | IA (favourable); IC2 (selected cases only); IC3/IB/II–IV = contraindicated |
| Histology | Confirmed HGSC — not HGEC (high-grade endometrioid) which has worse FS outcomes |
| Surgical staging | Comprehensive staging mandatory before FS decision |
| Contralateral ovary | Macroscopically and histologically normal |
| Uterus | Normal endometrium (hysteroscopy preferred) |
| Patient desire | Strong, informed wish to preserve fertility |
| Genetic testing | BRCA/other germline testing mandatory |
| Center expertise | Must be performed by team with gynecologic oncology + reproductive medicine expertise |
| Chemotherapy | Adjuvant platinum-based chemotherapy recommended for all HGSC regardless of stage IA |
Key References
- Berek & Novak's Gynecology, Fertility Preservation in Early-Stage Ovarian Cancer (pp. 2336–2337)
- ESGO/ESHRE/ESGE Fertility-Sparing Guidelines, Lancet Oncology 2024; Pocket Guidelines 2025
- Song BB et al. Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer. Obstet Gynecol 2024 [PMID: 38781594] — SEER data showing comparable survival in HGSC
- Gracia M et al. Current limits of conservative treatment in ovarian cancer. Curr Opin Oncol 2023 [PMID: 37498109]
- NCCN Guidelines for Patients: Ovarian Cancer, 2025
This is a shared conversation. Sign in to Orris to start your own chat.